Peri‑operative Management of Progesterone Therapy in Pregnant Patients

Continuation of Established Progesterone Therapy

• Maintain 17‑alpha‑hydroxyprogesterone caproate (17P) 250 mg intramuscularly each week in women with a prior spontaneous preterm birth; this regimen has been shown to reduce recurrent preterm birth by approximately 34 % (evidence from randomized trials). 1
• Continue vaginal progesterone (90 mg gel or 200 mg suppository daily) in women whose cervical length is ≤20 mm; treatment lowers the risk of delivery before 33 weeks and decreases composite neonatal morbidity and mortality (high‑quality trial evidence). 2
• Administer scheduled 17P injections without regard to the timing of non‑obstetric surgery; the injection schedule can be kept unchanged peri‑operatively. 1

Evidence of Efficacy for Specific Indications

Peri‑operative Considerations

• If a patient on 17P develops complications such as preterm premature rupture of membranes (PPROM), continuation of 17P is considered reasonable in the absence of contrary data. 3
• Progesterone is not an effective tocolytic agent for intra‑operative or post‑operative preterm contractions; it should not be used for primary, adjunctive, or maintenance tocolysis. 3

Pharmacokinetic and Route‑Specific Issues

• Oral drug absorption may be altered after bariatric surgery, but this does not affect intramuscular or vaginal progesterone formulations used for preterm‑birth prevention. 4

All statements are supported by the cited peer‑reviewed evidence and reflect current best practice for managing progesterone therapy around non‑obstetric surgery in pregnancy.

Progesterone Guidelines in Early Pregnancy

Preterm Birth Prevention

• The American College of Obstetricians and Gynecologists recommends 17-alpha-hydroxyprogesterone caproate (17P) 250 mg intramuscularly weekly from 16-20 weeks until 36 weeks for women with a singleton pregnancy and history of prior spontaneous preterm birth, based on a 34% reduction in recurrent preterm birth demonstrated in the landmark Meis trial 5, 6
• Vaginal progesterone should not be substituted for 17P in this population, as direct comparison trials show 17P is superior 5, 6
• For women without prior spontaneous preterm birth but with cervical length ≤20 mm detected at around 24 weeks, vaginal progesterone (90 mg gel or 200 mg suppository) daily from diagnosis until 36 weeks is recommended 7, 8, 9

Populations Where Progesterone is NOT Effective

• Progesterone has no proven benefit and should not be used for multiple gestations (twins, triplets) regardless of cervical length or prior history 9
• Progesterone has no proven benefit and should not be used for symptomatic preterm labor 9
• Progesterone has no proven benefit and should not be used for preterm premature rupture of membranes (PPROM) 9
• Progesterone has no proven benefit and should not be used for singleton pregnancies without risk factors (no prior preterm birth and normal cervical length) 7

Formulation Matters

• 17P intramuscular is not interchangeable with vaginal progesterone for women with prior spontaneous preterm birth 5, 6